VYNE Therapeutics (VYNE) Common Equity (2016 - 2026)

VYNE Therapeutics' Common Equity history runs 11 years deep, the most recent figure standing at $24.6 million for Q1 2026.

• Quarterly Common Equity fell 44.17% year-over-year to $24.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.6 million (down 44.17% YoY) and the FY2025 annual result came in at $27.8 million, down 46.69% from the prior year.
• Common Equity was $24.6 million for Q1 2026 at VYNE Therapeutics, down from $27.8 million in the prior quarter.
• Across five years, Common Equity topped out at $88.7 million in Q4 2023 and bottomed at $11.5 million in Q3 2023.
• A 5-year average of $45.5 million and a median of $42.1 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity sank 71.29% — and 2024, when it jumped 452.26%.
• VYNE Therapeutics' Common Equity stood at $31.2 million in 2022, then jumped by 184.39% to $88.7 million in 2023, then sank by 41.3% to $52.1 million in 2024, then plunged by 46.69% to $27.8 million in 2025, then slipped by 11.27% to $24.6 million in 2026.
• Business Quant data shows VYNE's Common Equity at $24.6 million in Q1 2026, $27.8 million in Q4 2025, and $38.9 million in Q2 2025.